Advertisement

Topics

Oncogenic BRAF in cancer - Biotech, Pharma and Life Science Channel

12:31 EDT 27th March 2017 | BioPortfolio

Oncogenic BRAF can result from mutations in the BRAF gene, which may cause the protein to become overactive. The most common alteration in the BRAF gene leads to the BRAFV600E mutation. Mutations in the BRAF gene allow for BRAF to signal independently of upstream cues, and result in overactive downstream signaling via MEK and ERK. This, in turn, leads to excessive cell proliferation and survival, independent of growth factors.

Source: http://www.biooncology.com/research-education/braf/targeting

PubMed Articles [207 Associated PubMed Articles listed on BioPortfolio]

Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.

In unresectable or metastatic melanoma with a BRAF V600 mutation, combined BRAF/MEK targeted therapy improves clinical outcomes. Yet, disease progression because of acquired resistance occurs in the m...

Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.

Vemurafenib and dabrafenib, two Food and Drug Administration-approved selective BRAF kinase inhibitors (BRAFi), have revolutionized the targeted therapy of cutaneous melanoma. Off-target effects of th...

Clinical Characteristics and Whole Exome/Transcriptome Sequencing of Coexisting Chronic Myeloid Leukemia and Myelofibrosis.

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell (HSC) disorders that can be classified on the basis of genetic, clinical, phenotypic features. Genetic lesions such as JAK2 mutat...

Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.

We assessed the associations between FDG uptake in primary papillary thyroid carcinomas (PTCs) and clinicopathological features, including the BRAF V600E mutation, using quantitative and qualitative a...

Genomics of Hairy Cell Leukemia.

Hairy cell leukemia (HCL) is a chronic mature B-cell neoplasm with unique clinicopathologic features and an initial exquisite sensitivity to chemotherapy with purine analogs; however, the disease rela...

Genomics of Multiple Myeloma.

Multiple myeloma (MM) is characterized by wide variability in the chromosomal/genetic changes present in tumor plasma cells. Genetically, MM can be divided into two groups according to ploidy and hype...

Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.

A dynamic sandwich assay on magnetic beads for selective detection of single-nucleotide mutations at room temperature.

Single-nucleotide mutation (SNM) has proven to be associated with a variety of human diseases. Development of reliable methods for the detection of SNM is crucial for molecular diagnosis and personali...

Beyond the BRAF(V)(600E) hotspot - Biology and clinical implications of rare BRAF gene mutations in melanoma patients.

BRAF mutations can be found in approximately 50% of melanomas, whereas the most common BRAF mutation is the substitution of a valine residue at codon 600 to glutamic acid. BRAF(V)(600E) occurs in up t...

Clinicopathologic characteristics of head and neck carcinoma showing thymus-like element.

Objective: To investigate clinicopathological features of carcinoma showing thymus-like elements (CASTLE) in the head and neck regions. Methods: Clinicopathological data of 7 patients with CASTLE in t...

News Articles [67 Associated News Articles listed on BioPortfolio]

Array Withdraws NDA for Anticancer Drug Binimetinib

Array BioPharma reported over the weekend that it is withdrawing its NDA for approval of binimetinib (MEK162) monotherapy in the treatment of NRAS-mutant melanoma. The firm said discussions with and f...

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data conf...

Biodesix® and Progenetics Announce Distribution Agreement for Israel

BOULDER, Colo., March 09, 2017 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Boulder, CO, USA) and Progenetics LTD (Tel Aviv, Israel) announced today that they have entered into an international agreement w...

Xynomic In-Licenses Second Oncology Drug Candidate in $60 Million Deal

Xynomic Pharma, a US-China oncology startup, has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana. It will be teste...

[Comment] A step forward for patients with -mutant melanoma

Metastatic melanoma is driven by activation of the MAPK pathway in most patients. Mutations in BRAF, present in approximately 40–50% of patients' tumours, are the most common activators of the MAPK ...

CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner

Cost-effectiveness compared for metastatic melanoma treatments

(HealthDay)—For patients with BRAF wild-type metastatic melanoma, first-line pembrolizumab (PEM) every three weeks followed by second-line ipilumumab (IPI), or first-line nivolumab (NIVO) followed b...

[Comment] A second chance for success with BRAF and MEK inhibitors in melanoma

Activating mutations in BRAF can be detected in about 40% of patients with metastatic melanoma and these mutations are disproportionately found in patients younger than 50 years of age.1 Treatment of ...

[Articles] Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Rechallenge with dabrafenib plus trametinib showed anti-tumour activity in patients who had previously progressed on BRAF inhibitors and as such, rechallenge represents a potential new treatment optio...

Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition

As a central element within the RAS/ERK pathway, the serine/threonine kinase BRAF plays a key role in development and homeostasis and represents the most frequently mutated kinase in tumors. Consequen...

Events [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

NewGene Limited

The demand for testing individuals for genetic disorders or cancers that have arisen from acquired genetic variations is growing year on year.  This is being driven by advances in medical genet...

Clinical Trials [88 Associated Clinical Trials listed on BioPortfolio]

Molecular and Histological Characteristics of Serrated Lesions of the Colon

Different subtypes of serrated lesions have been recently described. Among them, both sessile serrated polyp/adenoma (SSP/A) and traditional serrated adenoma (TSA) could have malignant pot...

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

The purpose of the study is to determine safety and tolerability of the combination of talimogene laherparepvec in combination with dabrafenib and trametinib in BRAF mutated advanced melan...

IV Ascorbic Acid in Advanced Gastric Cancer

Linus Pauling and Dr Ewan Cameron have published two retrospective studies about using high dose vitamin C to treat cancer patients forty years ago. Their studies have shown that high dose...

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma • To evaluate the overall radiological complete response rate in patients with stage IIIB/C melanoma af...

Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery

Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperativ...

Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown...

IV Ascorbic Acid in Advanced Colorectal Cancer

Preclinical study has shown that human colorectal cancer cells harboring KRAS or BRAF mutations are selectively killed by high levels of ascorbic acid (AA). High dose of AA impairs tumor g...

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF ...

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

Rationale: The combination of ipilimumab and nivolumab induces relatively high response rates and promising response depth in late stage melanoma. Nevertheless, it takes time till respons...

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma

The goal of this clinical research study is to learn if nivolumab and trametinib (with or without dabrafenib) can help to control metastatic melanoma in patients who have a BRAF, NRAS, or ...

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search
Advertisement
 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

review and buy Oncogenic BRAF in cancer market research data and corporate reports here

Channels Quicklinks